Researchers have developed a novel brain tumor test that surgical experts have dubbed a game changer. This is because the test collapses the needed time to obtain an accurate diagnosis to just hours rather than multiple weeks as has been the case.
Surgeons say this new approach can dramatically improve the treatment and care that patients receive after this “ultra-fast” diagnostic tool is used.
University of Nottingham scientists, together with a team from the NHS Trust of University of Nottingham Hospitals (NUH) developed this method. Their approach has caused a stir in UK hospitals and many are collecting data on the method alongside the conventional diagnostic methods they have been using. Their aim is to further document its efficacy.
Study findings which were published on Wednesday indicate 100% accuracy rate from the 50 surgeries in which this method has been used to identify the specific tumor type that a patient is suffering from.
Currently, at least 100 types of brain tumors exist. Clinicians must know the exact type a patient has in order to decide the specific treatment needed. Before this test, patients needed to undergo surgery so that a sample is removed for extensive examination and testing in order to classify the tumor.
Definitive results often took several weeks, sometimes even eight weeks elapse before a diagnosis is made. These methods aren’t 100% accurate, but the challenge is that once that diagnosis is in and the tumor type calls for aggressive surgery to remove as much of the growth as possible, the patient has to be called in for more surgery. This is a costly process in addition to subjecting patients and their caregivers to a lot of stress as they wait for the diagnosis.
The new method yields accurate results in approximately 90 minutes, which means a patient can be rapidly diagnosed shortly after the tumor sample is removed. The same surgical procedure in which a sample is obtained for testing can therefore be the same procedure through which extensive tumor removal can be undertaken.
This makes the test transformative because it reduces the number of surgical procedures a patient has to undergo and it allows treatment teams to quickly know what approach is needed to provide care to the patient.
Given that many brain tumors are very aggressive, this diagnostic tool developed by Professor Matt Loose allows prompt, appropriate treatment to be started without wasting valuable time. Prof. Loose leveraged software called ROBIN to develop this genetic test.
For all cancers, especially brain cancers, early diagnosis and treatment offer the best chance to improve clinical outcomes. This test could forever change how brain cancers are diagnosed. Prompt treatment using new therapeutics being developed by entities like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) or current treatments deemed appropriate for those diagnosed with a given brain cancer would improve the prognosis and outcomes for patients.
NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
